Urofollitropin is a urinary-derived follicle-stimulating hormone (FSH) that is extracted and purified from human urine samples. It consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids. The alpha subunit is glycosylated at Asn 51 and Asn 78 while the beta subunit is glycosylated at Asn 7 and Asn 24. Urofollitropin is typically used injected subcutaneously in combination with human chorionic gonadotropin (hCG) to induce ovulation. Urofollitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).
For treatment of female infertility
Universitätsklinik für Frauenheilkunde, Bern, Be, Switzerland
IRCCS San Raffaele, Milan, Italy
Universitair Ziekenhuis Brussel, Brussels, Belgium
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.